http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Zealand reports royalty revenue for the second quarter of 2017
-
Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
-
Zealand to regain control of elsiglutide
-
New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%
-
Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association (ADA) indicate use for treatment of severe hypoglycemia
-
Zealand to present at two international healthcare investor conferences in June 2017
-
CORRECTION: Zealand reports results for the first three months of 2017 (unaudited)
-
Zealand reports results for the first three months of 2017 (unaudited)
-
Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
-
Zealand reports Q1 2017 royalty revenue
-
Zealand hosts conference call on March 15 at 4 pm CET to present 2016 full-year results
-
Zealand reports Q4 2016 Lyxumia® royalty revenue
-
Notice of the date of Zealand's Annual General Meeting 2017 and of deadline for proposals for the agenda
-
Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
-
EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
-
Zealand reports that Sanofi announces Soliqua(TM) 100/33 now available in the U.S
-
Financial calendar for 2017
-
Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
-
The U.S. FDA approves Soliqua(TM) 100/33 for the treatment of adults with type 2 diabetes
-
CHMP issues positive opinion recommending Suliqua(TM) (iGlarLixi) for approval in the EU
